Nature Communications

NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial

2026-01-16

Full text

DOI https://doi.org/10.1038/s41467-026-68409-0